251. Histological and behavioral protection by (-)-nicotine against quinolinic acid-induced neurodegeneration in the hippocampus.
- Author
-
O'Neill AB, Morgan SJ, and Brioni JD
- Subjects
- Animals, Brain Diseases chemically induced, Brain Diseases drug therapy, Cognition Disorders chemically induced, Cognition Disorders pathology, Male, Maze Learning drug effects, Memory Disorders chemically induced, Memory Disorders pathology, Nicotine therapeutic use, Rats, Brain Diseases pathology, Hippocampus metabolism, Hippocampus pathology, Nerve Degeneration, Neuroprotective Agents pharmacology, Nicotine pharmacology, Quinolinic Acid adverse effects, Quinolinic Acid antagonists & inhibitors, Spatial Behavior drug effects
- Abstract
Injections of quinolinic acid (60, 180, and 600 nmol) in the dorsal hippocampus induced significant neurotoxicity that was evident 1 day after the injection. By day 3, pyramidal as well as granular cells were affected even at the lowest dose of quinolinic acid, an effect that persisted up to 20 days. Consistent with the histological findings, animals with bilateral injections in the dorsal hippocampus were cognitively impaired during acquisition and retention of spatial information in the water maze. A subacute treatment with (-)-nicotine (62 micromol/kg/day) delivered by subcutaneous minipumps prevented the histological and cognitive deficits induced by the bilateral quinolinic acid (60 nmol) injections. These data indicate that quinolinic acid can induce degeneration of both pyramidal as well as granule cells in the hippocampus, leading to cognitive impairments in the rat, and that activation of neuronal nicotinic acetylcholine receptors can prevent the neurodegenerative process induced by quinolinic acid., (Copyright 1998 Academic Press.)
- Published
- 1998
- Full Text
- View/download PDF